News Articles

Browse our entire archive of news articles, spotlight interviews, and other editorial pieces in one place.

Filters
Clear all
Showing 0 of 100
Keyword Search
Open Arrow
Article Type
Open Arrow
Company
Open Arrow
Clear all
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters
Tag
Close Icon

Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders

News
November 16, 2023
Cybin Inc.

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

News
November 15, 2023
Compass Pathways

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

News
November 9, 2023
Clearmind Medicine

Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder

News
November 1, 2023
Cybin Inc.

Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program

News
October 25, 2023
Cybin Inc.

Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

News
October 24, 2023
Cybin Inc.

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

News
October 23, 2023
Cybin Inc.

Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial

News
September 26, 2023
Cybin Inc.

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

News
September 8, 2023
Compass Pathways

Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program

News
September 7, 2023
Optimi Health

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

News
September 6, 2023
Clearmind Medicine

Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001

News
September 6, 2023
Awakn Life Sciences

Otsuka Pharmaceutical to Acquire Mindset Pharma

News
August 31, 2023
Mindset Pharma

Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

News
August 30, 2023
Nova Mentis Life Science

Cybin to Acquire Small Pharma Inc.

News
August 28, 2023
Cybin Inc.

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

News
August 16, 2023
Compass Pathways

Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program

News
August 15, 2023
Cybin Inc.

Filament Health Announces Fda Approval Of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate Pex010

News
August 8, 2023
Optimi Health

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

News
August 8, 2023
Algernon Pharmaceuticals

Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder

News
August 3, 2023
Cybin Inc.
No results found.
There are no results with this criteria. Try changing your search.
HomeNewsCompaniesSpotlightsSubscribe
Instagram
Twitter
RSS Feed
Email Us
©XXXX Psychedelic Finance. All rights reserved.
Privacy Policy
Core One Labs Inc.
Creso Pharma
Cybin Inc.
Enveric Biosciences
Field Trip Health
Filament Health
Havn Life
Levitee Labs
MINDCURE
Mydecine Innovations Group
NeonMind Biosciences Inc.
Novamind Inc.
Numinus
Optimi Health
Pharmather
PsyBio Therapeutics
Psyched Wellness
Psyence Group
Pure Extracts Corp
Silo Wellness
The Good Shroom Co
Tryp Therapeutics
Wesana Health
Aja Ventures
Albert Labs
Algernon Pharmaceuticals
Apex Labs Ltd.
B.More
Beckley Foundation
BetterLife Pharma
Bexson Biomedical
Biomind Labs
Bionomics
Braxia Scientific Corp.
Bright Minds
CB Therapeutics
Ceruvia Lifesciences
Clairvoyant Therapeutics
Clearmind Medicine
Clexio Biosciences
Cognetivity Neurosciences
Cube Psytech
Delic
Delix Therapeutics
Diamond Therapeutics
Ehave
FSD Pharma
Fluence
Freedom to Operate
HMNC Brain Health
Horizons ETFs Management Inc.
Incannex Healthcare
IntelGenx
Irwin Naturals
Ixtlan Bioscience
Johns Hopkins Medicine
MYND Diagnostics
Mind Medicine (MindMed)
MindBio Therapeutics
Mindset Pharma
Mycotopia Therapies
Mycrodose Therapeutics
Neural Therapeutics
Ninnion
Nirvana Life Sciences
Nova Mentis Life Science
Origin Therapeutics
Osmind
Pasithea Therapeutics
Pharmala Biotech Holdings
Psilera
Psilotec Health Solutions
PsyRx
Psylo
Quantified Citizen
Reunion Neuroscience
Revitalist Lifestyle and Wellness
Revive Therapeutics
Seelos Therapeutics
Small Pharma
Telescope Innovations
TheraPsil
TripSitter
Universal Ibogaine
Wellbeing Digital Sciences
Woke Pharmaceuticals
Woven Science
ATAI Life Sciences
Awakn Life Sciences
Beckley Psytech
Compass Pathways
Doseology Sciences
EI.ventures
Eleusis
Entheon Biomedical
Gilgamesh Pharmaceuticals
GoodCap Wellness
Lobe Sciences
Lophora
MAPS